Icra sees pharma industry growth tapering to 7-10% over FY18-FY20Post published:July 4, 2017Post category:Industry NewsThe Indian pharma industry is likely to witness a slowdown in growth because of pricing pressure and regulatory interventions in the US, according to an Icra report Source: Livemint.com (http://www.livemint.com/rss/industry)Read more articles Previous PostIndoStar Capital close to acquiring ICICI Home Finance Next PostGST rates: Footwear to cost more as firms look to increase prices by 5-7% You Might Also Like Fluke introduces Fluke Intrinsically Safe Flashlights October 1, 2018 Global investors line up for stake in Bhushan Steel August 7, 2017 LASORTING Upgrade Allows Control of Entire Production Process November 26, 2019